Menu Search
Equities

Cipher Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
PHE:MUN

Cipher Pharmaceuticals Inc

Actions
  • Price (EUR)8.15
  • Today's Change-0.90 / -9.94%
  • Shares traded1.00
  • 1 Year change-9.94%
  • Beta0.8196
Data delayed at least 15 minutes, as of Feb 11 2026 12:26 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early-to-late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.

  • Revenue in CAD (TTM)67.82m
  • Net income in CAD23.53m
  • Incorporated2020
  • Employees61.00
  • Location
    Cipher Pharmaceuticals Inc5750 Explorer Drive,, Suite 404MISSISSAUGA L4W 0A9CanadaCAN
  • Phone+1 (905) 602-5840
  • Websitehttps://www.cipherpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.